Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma

Abstract

Background

HIF-1alpha and CAIX proteins are commonly expressed under hypoxic conditions, but other regulatory factors have been described as well. Pancreatic ductal adenocarcinoma (PDAC) is characterized by hypoxia and strong stromal reaction and has a dismal prognosis with the currently available treatment modalities.

Methods

We investigated the expression and prognostic role of HIF-1alpha and CAIX in PDAC series from Northern Finland (n = 69) using immunohistochemistry.

Results

In our PDAC cases, 95 and 85% showed HIF-1alpha and CAIX expression, respectively. Low HIF-1alpha expression correlated with poor prognosis, and multivariate analysis identified weak HIF-1alpha intensity as an independent prognostic factor for PDAC-specific deaths (HR 2.176, 95% CI 1.216–3.893; p = 0.009). There was no correlation between HIF-1alpha and CAIX expression levels, and the latter did not relate with survival.

Conclusions

Our findings are in contrast with previous research by finding an association between low HIF-1alpha and poor prognosis. The biological mechanisms remain speculative, but such an unexpected relation with prognosis and absence of correlation between HIF-1alpha and CAIX suggests that the prognostic association of HIF-1alpha may not directly be linked with hypoxia. Accordingly, the role of HIF-1alpha might be more complex than previously thought and the use of this marker as a hypoxia-related prognostic factor should be addressed with caution.

Electronic supplementary material

The online version of this article (10.1186/s12957-018-1432-4) contains supplementary material, which is available to authorized users.

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide [1]. Surgical and oncological treatment of PDAC is arduous for the patient but still, the long-term survival rates are low [2]. Surgical resection [3], often in combination with adjuvant chemotherapy [4], is the only curative treatment of PDAC.

PDAC is characterized by hypoxia and neovascularization [5, 6]. Hypoxia-inducible factor 1 alpha (HIF-1alpha) is a protein expressed under hypoxic conditions [7]. HIF-1alpha regulates tumor angiogenesis [8], and high level of HIF-1alpha has been linked to tumor neoangiogenesis in PDAC [9–13]. Previous studies have indicated that strong HIF-1alpha expression associates with poor overall survival of patients with PDAC [9, 14–20]. Carbonic anhydrase 9 (CAIX) is a membrane-associated protein that is regulated by HIF-1alpha under hypoxic conditions [21]. Increased expression has been found in PDAC [22], and an association between abundance of CAIX and poor prognosis has been suggested [23].

The aim of the present study was to investigate the expression of and association between HIF-1alpha and CAIX expression and prognosis in a Finnish PDAC cohort.

Methods

Patients

Some 69 patients underwent surgery for PDAC in Oulu University Hospital during 1993–2011. For these patients, archival paraffinized specimens were collected from the pathology archive of the hospital. Clinical data was extracted from the patient records (Table 1). Statistics Finland provided complete survival data until the end of 2015. An expert gastrointestinal pathologist (TJK) confirmed the PDAC diagnosis. The majority of the patients underwent pancreaticoduodenectomy (i.e., Whipple procedure; n = 56) while two patients had distal pancreatectomy and 11 patients had total pancreatectomy. Macroscopic venous invasion was observed in six of the patients during the operation. Tumor grade was not determinable in 16 patients. Patients had a median age of 66 years at diagnosis, the range being 36–77 years. The median follow-up time in the cohort was 21 months (range 1–173 months). Of the 69 patients, 12 (17%) developed distant metastasis within 6 months of surgery, but stage at the time of surgery was used in the analyses. Samples of ischemic colon (n = 4) were used as a positive control for HIF-1alpha. The study was approved by the Oulu University Hospital Ethics Committee (EETTMK:81/2008) and by the National Authority for Medicolegal Affairs (VALVIRA).

Table 1.

Baseline characteristics of 69 patients with resected pancreatic ductal adenocarcinoma

Patient clinical data	n/N	Percent
Age at diagnosis
< 65	34/69	49
≥ 65	35/69	51
Sex
Male	36/69	52
Female	33/69	48
Tumor size (mm)
< 30	23/69	33
30–40	31/69	45.0
> 40	15/69	22
Tumor stage
I	18/68	26
II	44/68	65
III–IV	6/68	9
Lymph nodes*
Negative	34/68	50
Positive	34/68	50
HIF-1alpha
Strong	28/64	44
Weak	36/64	56
BMI**
< 25	19/46	41
> 25	27/46	59
Smoking
Smoker**	14/33	42
Ex-smoker	7/33	21
Non-smoker	12/33	36
Alcohol usage**
Heavy	7/24	29
Moderate-No	17/24	71
Chronic pancreatitis***
Present	39/69	57
Absent	30/69	43

^*Lymph node status and tumor stage were available from 68 patients

^**BMI was missing from 22, smoking status from 36 patients, and alcohol usage from 45 patients

^***Present or absent chronic pancreatitis reported pre-operatively in the patient records or in the histological analysis

Immunohistochemistry

Immunohistochemistry was performed on representative tissue block sections, chosen using hematoxylin and eosin stainings. Commercial monoclonal mouse antibody against HIF-1alpha (NB100-105 IgG2b, Clone H1alpha67, Novus Biologicals, Littleton, CO) has previously been validated for use in formalin-fixed paraffin-embedded material [24–26] and was used at a dilution of 1:300. Dako Envision flex kit (Dako, Copenhagen, Denmark) with high-temperature antigen retrieval in Tris-EDTA buffer for 20 min (pH 9.0) was used for detection of antibody reaction and diaminobenzidine (Dako basic DAB-kit) as a chromogen. Dako Autostainer (Dako) was used for the stainings.

The previously described monoclonal antibody M75 was used to recognize the N-terminal domain of human CAIX [27], with normal rabbit serum acting as negative control. Immunohistochemical staining was performed using automated Lab Vision Autostainer 480 (ImmunoVision Technologies Co., Brisbane, CA) and polymer-based Power Vision+™ Poly-HRP IHC Kit reagents (ImmunoVision Technologies, Co.) in room temperature, as described earlier [28].

Three series of controls (primary antibody omitted, primary antibody replaced with mouse primary antibody isotype control, and staining with irrelevant CD3-antibody) were performed. Specimens of ischemic intestine were used as positive controls for HIF-1alpha staining.

Histological analysis

Two (HIF-1alpha) or three investigators (CAIX), blinded to outcomes, evaluated the specimens as previously described [29, 30]. HIF-1alpha (n = 64) and CAIX (n = 65) stainings of PDAC could be evaluated due to availability of tissue section material. Separate assessment of adjacent normal pancreas was conducted, including normal duct epithelium and exocrine parenchyma (n = 35 and n = 39 for HIF-1alpha and CAIX, respectively). Separate assessment of membranous, cytoplasmic, and nuclear staining in the tumor cells was conducted with scoring of intensity on a four-point scales 0–3 (absent to strong). For statistical analysis, nuclear HIF-1alpha intensity and membranous CAIX intensity were divided by the median level into two groups, weak and strong. The percentage of positively stained cells was recorded using a five-point scale ranging from 0 to 4: 0 = < 1%, 1 = 1–10%, 2 = 11–49%, 3 = 50–80%, and 4 = > 80%. A score was calculated using a formula described earlier [26]: Score = [(1 + intensity)/3] × proportion of positive cells (0–4), resulting in score ranging from 0 to 5.33. This scoring allowed the percentage of stained cells to have greater impact on the score than staining intensity. The median score (2.167) was used to dichotomize the expression into two groups (weak and strong). The mean value of the separate assessments was used in the statistical analysis if the inter-observer difference < 1 step in intensity and < 30% in percentage. Greater discrepancies were jointly re-evaluated, resulting in a single score. According to these criteria, only one specimen needed re-evaluation for CAIX intensity.

Statistical analysis

IBM SPSS statistics for Windows, version 22.0, Armonk, NY: IBM Corp, was used for all analyses. Nuclear HIF-1alpha and membranous CAIX intensity between cancerous tissue and adjacent normal pancreatic tissue was compared with Wilcoxon paired test. Differences between prognostic and clinicopathological variables (TNM staging, tumor grade, tumor size, BMI, and sex) were calculated with the chi-square test. Life tables were calculated with Kaplan-Meier method, and survival curves compared with log-rank test. Cox proportional hazards model provided hazard ratios (HRs) and 95% confidence intervals (CIs) for each variable. The following factors were analyzed: nuclear HIF-1alpha staining intensity (weak, or strong), age at diagnosis (< 65, or ≥ 65 years), sex (male or female) and tumor stage (I, II, or III–IV). Correlation between nuclear HIF-1alpha expression and membranous CAIX expression was obtained by Spearman’s non-parametrical correlation. P < 0.05 was considered statistically significant.

Results

HIF-1alpha and CAIX are expressed in normal pancreas and in pancreatic ductal adenocarcinoma

For HIF-1alpha staining, normal pancreatic tissue adjacent to PDAC was present in 35/64 cases. In this adjacent normal pancreas, there was positive nuclear expression of HIF-1alpha in 19/35 (54%) cases and positive cytoplasmic HIF-1alpha expression in all of the studied cases (35/35). Nuclear and cytoplasmic staining was present in the exocrine cells and ductal epithelium. Positive nuclear HIF-1alpha staining was more prevalent and extensive in cancerous tissue, where it was found in 61/64 (95%) cases (mean proportion of positive cells 37%, SD 24, range 0–95, mean intensity 2.2, SD 0.7, range 0–3), as compared with the adjacent normal pancreatic tissue (mean proportion of positive cells 19%, SD 21, range 0–55, mean intensity 1.1, SD 1.1, range 0–3); (p < 0.001) (Fig. 1a, c, d).

Fig. 1.

HIF-1alpha and CAIX expression in PDAC and adjacent normal pancreatic tissue. Adjacent normal exocrine pancreas with weak nuclear and cytoplasmic HIF-1alpha staining (a). Adjacent normal pancreatic tissue with weak membranous CAIX staining in the ducts and absent staining in exocrine pancreatic tissue (b). PDAC with weak (intensity 1) nuclear and cytoplasmic HIF-1alpha staining (c). PDAC with strong (intensity 3) nuclear and moderate (intensity 2) cytoplasmic HIF-1alpha staining (d). PDAC with weak to moderate (intensity 1–2) membranous CAIX staining (e). PDAC with strong (intensity 3) membranous CAIX staining (f)

In PDAC, cytoplasmic HIF-1alpha expression was present in 61/64 (95%) cases (mean proportion of positive cells 82%, SD 29, range 0–100, mean intensity 1.4, SD 0.6, range 0–3) and was more prevalent compared to adjacent normal pancreatic tissue (mean proportion of positive cells 95%, SD 17, range 0–100, mean intensity 1.9, SD 0.7, range 0–3); (p = 0.009) (Fig. 1a, c, d). Co-expression of nuclear and cytoplasmic staining was present in 60/64 cases. There was no correlation in HIF-1alpha expression between adjacent normal pancreas and carcinoma cells.

In CAIX stainings, adjacent normal pancreatic tissue was present in 39/65 cases. CAIX was expressed in normal pancreas in 27/39 (69%) cases (mean proportion 12.1%, SD 15.4, range 0–73, mean intensity 0.76, SD 0.56, range 0–2). The expression was mainly membranous and located in the ductal epithelial cells. In PDCA, CAIX was expressed in the cell membrane of the cancer cells (Fig. 1b, e, f), staining being present in 55/65 (85%) cases (mean proportion 38.8%, SD 29.9, range 0–100, mean intensity 1.65, SD 0.97, range 0–3). Membranous CAIX staining was significantly increased in cancerous tissue compared to adjacent normal pancreatic tissue (p < 0.001). There was no correlation in CAIX expression between adjacent normal pancreas and carcinoma cells.

Control stainings for HIF-1alpha

In order to confirm performance of the HIF-1alpha staining and to exclude the possible bias caused by unspecific positive staining, samples of ischemic colon (n = 4) were stained with HIF-1alpha antibody for positive control. As expected, mucosal epithelium showed positive nuclear HIF-1alpha staining in the ischemic cells, with the staining intensity gradually increasing from absent to strong in the cells adjacent to ischemic necrosis (Additional file 1: Figure S1). For a negative control PDAC, samples showing high nuclear HIF-1alpha were stained with CD3 antibody (n = 3). CD3 staining was present only in the lymphocytes and not in the carcinoma cells (Additional file 1: Figure S1).

Correlation between HIF-1alpha and CAIX

There was no correlation between nuclear or cytoplasmic HIF-1alpha expression intensity and membranous CAIX intensity in carcinoma cells. No correlation was found between HIF-1alpha and CAIX in adjacent normal pancreatic tissue. Also, no correlation in HIF-1alpha or CAIX between adjacent normal pancreas and carcinoma cells was observed.

Clinicopathological variables and HIF-1alpha and CAIX expression

No correlation between nuclear HIF-1alpha expression and clinicopathological variables (TNM stage, tumor grade, tumor size, BMI, and sex) was found, Table 2. Males showed a weaker membranous CAIX staining compared to females (p = 0.038). There were no other correlations between membranous CAIX staining and the clinicopathological variables (Table 2).

Table 2.

Intensity of HIF-1alpha and CAIX compared to clinicopathological variables in pancreatic ductal adenocarcinoma. Statistically significant p values are italicized

Variable	n/N	Nuclear HIF-1alpha intensity, n			n/N	Membranous CAIX intensity, n
		Weak	Strong	p		Weak	Strong	p
pT
T1	4/64	1	3	0.439	4/65	4	0	0.533
T2	22/64	11	11		22/65	15	7
T3	32/64	20	12		33/65	23	10
T4	6/64	4	2		6/65	5	1
Lymph nodes
Positive	31/64	16	15	0.556	32/65	23	9	0.823
Negative	32/64	19	13	*	32/65	23	9	*
Stage
I	18/63	7	11	0.236	18/64	13	5	0.794
II	39/63	24	15	*	40/64	28	12	*
III–IV	6/63	4	2		6/64	5	1
Tumor grade
1	9/63	4	5	0.351	9/64	6	3	0.344
2	28/63	17	11	**	28/64	22	6	**
3	13/63	9	4		13/64	11	2
Tumor size
> 30 mm	42/64	23	19	0.475	43/65	30	13	0.370
< 30 mm	22/64	13	9		22/65	17	5
BMI
> 25	25/43	15	10	0.366	26/44	19	7	0.186
< 25	18/43	9	9	***	18/44	16	2	***
Sex
Male	35/64	19	16	0.463	35/65	29	6	0.038
Female	29/64	17	12		30/65	18	12

^*Lymph node status was unavailable for one patient

^**Tumor grade was missing from 16 patients

^***BMI was available only for 47 patients

BMI, smoking, alcohol consumption, or chronic pancreatitis and HIF-1alpha and CAIX expression

BMI, smoking, alcohol consumption, or chronic pancreatitis were not associated with HIF-1alpha or CAIX expression. Chronic pancreatitis did not affect patient survival (data not shown). Numbers and percentages of BMI, smoking status, alcohol usage, and chronic pancreatitis are summarized in Table 1.

Survival, HIF-1alpha and CAIX expression: univariate and multivariate analysis

The association between HIF-1alpha and CAIX expression and 5-year survival was analyzed. Mean 5-year survival was 12 months shorter in the group with weak nuclear HIF-1alpha intensity (21.5 months; 95% CI 15.9–27.0) as compared with strong intensity (34.2 months; 95% CI 27.0–41.3; p = 0.007, log-rank; Fig. 2). Multivariate analysis identified weak nuclear HIF-1alpha intensity as an independent prognostic factor for PDAC-specific deaths (HR 2.176, 95% CI 1.216–3.893, p = 0.009; Additional file 2: Table S1).

Fig. 2.

Kaplan-Meier curve visualizing the effect of weak nuclear HIF-1alpha intensity on patient 5-year survival. Mean survival time for patients with weak nuclear HIF-1alpha intensity (n = 36) was 21.5 months, as patients with strong nuclear HIF-1alpha intensity (n = 28) mean survival time was 34.2 months; (p = 0.007 log-rank)

Similarly, using HIF-1alpha score to address the simultaneous impact of the intensity and extent of the staining, an association between weak HIF-1alpha expression and poor survival was found. Patients with a weak HIF-1alpha score had significantly shorter survival time (22.5 months; 95% CI 16.3–28.6) compared to patients with a strong score (31.5 months; 95% CI 24.7–38.2; p = 0.050). In multivariate analysis, weak HIF-1alpha score showed an increased point estimate for hazard ratio similar to HIF-1alpha intensity, but the association was not statistically significant (HR 1.7, 95%CI 0.985–3.031; Additional file 3: Table S2).

CAIX expression was not associated with 5-year survival (p = 0.393). Furthermore, cytoplasmic HIF-1alpha expression was not associated with 5-year survival (p = 0.930).

Discussion

The results of the present study suggest that absent to weak nuclear HIF-1alpha expression might be an independent predictor of poor survival. No significant association between CAIX expression and survival or the expression levels of HIF-1 alpha and CAIX was found.

Limitations of the present study include its retrospective nature, relatively small sample size, and low number of T4 cases in the analysis due to the inoperable nature of these tumors (Table 2).

Several previous studies have proposed an association between strong expression of HIF-1alpha and poor prognosis in PDAC [14]. Similarly, increased levels of CAIX in PDAC [22, 31] and impact on poor prognosis have been suggested [11, 23]. Although association with strong expression of HIF-1alpha and adverse prognosis has been reported in some other cancer types as well [32–35], there are also contrary reports, including association of weak HIF-1alpha expression and poor prognosis in squamous cell carcinoma of the oral cavity [36–38] and breast cancer [39].

The mechanism linking high HIF-1alpha expression and good prognosis remains speculative. In previous studies, HIF-1alpha associated commonly with other hypoxia-related markers, such as CAIX, suggesting hypoxia-dependent HIF-1alpha expression [14]. The absence of correlation between HIF-1alpha and CAIX in PDAC cells in the present study supports the hypothesis that rather than being regulated by hypoxia, HIF-1alpha expression could be modified by other factors. These factors include alterations in various tumor suppressor genes and oncogenes [36, 40–45]. Previous studies have indicated that such oxygen-independent HIF-1alpha expression results in a diffuse expression pattern throughout the tumor. This staining pattern is typically not limited to ischemic areas. Such diffuse expression has been reported in brain tumors, breast cancer, and oropharyngeal cancers [46–49]. We hypothesize that the loss of HIF-1alpha in tumors with adverse prognosis could just be a marker of the simultaneous presence of multiple severe genetic aberrations in PDAC cells. Furthermore, abundant expression of HIF-1alpha and the associated good prognosis could be manifestations of fewer genetic and functional aberrations. In support of such interpretation, HIF-1alpha expression in the adjacent normal pancreatic tissue was common, 54% of the cases showing nuclear HIF-1alpha expression, and in all cases, HIF-1alpha was detected in cytoplasm. Furthermore, 69% of the cases showed positive CAIX expression in adjacent normal pancreatic tissue. We hypothesize that HIF-1alpha expression in the normal pancreatic cells indicates their physiological abilities to respond to the relative lack of oxygen. Furthermore, we suggest that HIF-1alpha expression in the cancer cells could indicate their physiological ability to respond to hypoxia. Accordingly, high HIF-1alpha expression in the cancer cells could be a marker of the less malignant nature of these cells. This matter remains hypothetical and further evidence to confirm the association between HIF-1alpha levels and mutations in the oncogenes and tumor suppressor genes is needed.

In previous studies, it has been shown that oxidative phosphorylation is associated with chemoresistance and aggressiveness in pancreatic cancer [50]. Cells use glucose in a process of glycolysis where ATP and lactate are formed. Another mechanism involves glycolysis, which is followed by pyruvate metabolism in the Krebs cycle and oxidative phosphorylation in the mitochondria [51]. Oxidative phosphorylation is reduced in many cancers, and association with poor outcome has been reported [52]. It has been shown that pancreatic cancer is metabolically heterogeneous. Furthermore, the number of tumor cells relying on oxidative phosphorylation is high in pancreatic cancer [53]. These tumor cells are typically highly metastatic and have more tumorigenic potential than the cells less reliant to oxidative phosphorylation [54]. Furthermore, studies investigating human colon carcinoma cells in vitro have shown that HIF-1alpha reduces oxidative phosphorylation [55]. The HIF-1alpha expression detected in our material could be an indicator for reduced oxidative phosphorylation and reduced tumorigenic properties. However, this hypothetical association needs to be assessed in further studies.

Methodological issues in previous studies could also contribute to the discrepant findings about the prognostic role of HIF-1alpha, as summarized in Table 3. Endogenous biotin present in normal and neoplastic pancreas can lead to false positive cytoplasmic or nuclear staining, thus possibly explaining many of the previous findings [56–58]. Furthermore, the use of negative control is not reported in all of the previous studies [14]. This, together with the application of different antibodies and considering cytoplasmic staining of HIF-1alpha in the survival analysis, could contribute to the previous discordant results (Table 3).

Table 3.

Immunohistochemical detection methods in the original articles included in the meta-analysis by Ye et al. [14]

Paper	Patients (n)	Immunohistochemistry procedures	HIF-1alfa antibody source and clone	Biotin based	Prognostic effect of HIF-1alpha	Reference
Sun et al. 2007	58	Supervision™, negative controls	BA0912, Wuhan Boster, China	?	High nuclear and/or cytoplasmic HIF-1alpha ➔ poor overall survival	[10]
Zhu et al. 2013	63	Supervision™, negative controls	Not mentioned	?	High nuclear and/or cytoplasmic HIF-1alpha ➔ poor overall survival	[20]
Zhang et al. 2010	65	Biotinylated goat anti-mouse or anti-rabbit (Streptavidin/peroxidase), negative controls	Santa Cruz, CA, USA	Yes	High nuclear and/or cytoplasmic HIF-1alpha ➔ poor overall survival	[18]
Miyake et al. 2008	39	Avidin-biotin (Dako LSAB™), no negative controls mentioned	Novus Biologicals, Littleton, CO	Yes	High nuclear HIF-1alpha ➔ poor overall survival	[17]
Matsuo et al. 2014	100	Avidin-biotin, no negative controls mentioned	Not mentioned	Yes	High nuclear and/or cytoplasmic HIF-1alpha ➔ poor overall survival	[9]
Ide et al. 2007	41	Biotinylated anti-mouse, anti-rabbit antibody conjugated to a peroxidase-labeled dextran polymer (Dako EnVision+™), no negative control mentioned	Clone HI-67, Novus Biologicals, Littleton, CO	No	High nuclear and/or cytoplasmic HIF-1alpha ➔ worse disease free survival, no correlation between HIF-1alpha and overall survival	[16]
Spivak-Kroizman et al. 2013	129	Bond™ Polymer Refine Detection Kit, no negative control mentioned	BD Biosciences	No	High nuclear HIF-1alpha ➔ poor overall survival	[15]
Zhao et al. 2012	95	Streptavidin biotin-peroxidase, biotinylated secondary antibody, no negative control mentioned	sc-10790, Santa Cruz, CA, USA	Yes	HIF-1alpha localization not mentioned. High HIF-1alpha ➔ poor overall survival	[19]

Conclusion

In summary, weak nuclear HIF-1alpha expression associated with poor survival of the patients with PDAC in our material. CAIX was overexpressed in PDAC, but did not correlate with HIF-1alpha expression levels or prognosis, suggesting that factors other than hypoxia could also contribute to regulation of HIF-1alpha levels in PDAC and explain the effect on survival.

Abbreviations

CAIX

Carbonic anhydrase

HIF-1alpha

Hypoxia-inducible factor 1 alpha

PDAC

Pancreatic ductal adenocarcinoma

Authors’ contributions

JL, K-MH, and JI collected the patient clinical data. JL, OH, HH, and JHK analyzed and interpreted the data. SP participated in the immunohistochemical stainings. JL wrote the manuscript. JL, OH, HH, JHK, PL, JS, and TJK critically revised the manuscript. PL, JS, and TJK supervised the study. All of the authors read and approved the final manuscript.

Ethics approval and consent to participate

The use of the samples and the data inquiry were approved by the Oulu University Hospital Ethics Committee and by the National Authority for Medicolegal Affairs (VALVIRA); (EETTMK:81/2008).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.